Verastem reports 2-year RAMP 201 data for avutometinib-defactinib combo
Company says follow-up data reinforced durable responses and disease control in recurrent LGSOC, with no new safety signals.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.